TrialMenopause (New York, N.Y.)2020

Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.

Angelica Lindén Hirschberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.